Working… Menu

Pulmonary Involvement in Scleroderma: A Clinical Study of the Safety and Efficacy of Mycophenolate Mofetil in Scleroderma Patients With Lung Involvement

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00333437
Recruitment Status : Completed
First Posted : June 5, 2006
Results First Posted : May 17, 2013
Last Update Posted : November 13, 2013
Roche Pharma AG
Information provided by (Responsible Party):
University of California, San Francisco

Brief Summary:
Researchers from the Division of Pulmonary and Critical Care Medicine at University of California, San Francisco (UCSF) are conducting a study to evaluate whether mycophenolate mofetil (an immunosuppressive medication, trade named CellCept) is safe and effective for preventing the lung damage from scleroderma from getting worse.

Condition or disease Intervention/treatment Phase
Scleroderma, Systemic Drug: Mycophenolate mofetil Not Applicable

Detailed Description:

The proposed study is designed to evaluate the safety and efficacy of mycophenolate mofetil (CellCept) for the treatment of symptomatic pulmonary alveolitis due to systemic sclerosis (SSc). This study utilizes a prospective, open-label, experimental design.

Primary Hypothesis: The alveolitis in patients with SSc, as defined by decreased forced vital capacity (FVC), bronchoalveolar lavage (BAL), and High Resolution Chest Tomography (HRCT) is responsive to 1 year of daily mycophenolate mofetil therapy.

Secondary Hypothesis: Quality of life, six-minute walk and single-breath diffusing capacity for carbon monoxide (DLCO) improve in patients with SSc mediated alveolitis after therapy with mycophenolate mofetil. This response to therapy is associated with a change in the inflammatory cytokine profile present in BAL fluid.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 7 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Pulmonary Involvement in Scleroderma: Safety and Efficacy of Mycophenolate Mofetil in Scleroderma Patients
Study Start Date : May 2006
Actual Primary Completion Date : January 2009
Actual Study Completion Date : January 2009

Arm Intervention/treatment
Experimental: Treatment
Mycophenolate Mofetil
Drug: Mycophenolate mofetil

Primary Outcome Measures :
  1. Mean Change From Baseline in Forced Vital Capacity (FVC) [ Time Frame: Baseline, 12 months ]
    compare pre- and post-therapy FVC (post- minus pre-). Forced vital capacity (FVC) is the volume of air (liters) that can forcibly be blown out after full inspiration.

Secondary Outcome Measures :
  1. Mean Change in Bronchoalveolar Lavage (BAL) Components (Neutrophils, Eosinophils) [ Time Frame: Baseline, 12 months ]
    BAL samples were colleected from the affected lobe (as determined by lung CT scans) before beginning and after completing study therapy.

  2. Change in Shortness of Breath (Self-reported) [ Time Frame: Baseline, 12 months ]
    Participants reported frequency of shortness of breath experienced with exertion

  3. Mean Change in Six Minute Walk Distance [ Time Frame: 12 months ]
    Comparison of 6-minute walk distance before beginning and after completing study therapy

  4. Mean Change in Diffusion Capacity of the Lung for Carbon Monoxide (DLCO) [ Time Frame: 12 months ]
    DLCO was measured before beginning and after completion of study therapy

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   21 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • To participate in this study, patients must first undergo a BAL and HRCT. To be eligible to undergo HRCT and BAL (under the purview of this trial), prospective patients must meet the following criteria:

    • Aged 21-70.
    • Negative pregnancy test (with a sensitivity of at least 50 mIU/mL) for females of child-bearing potential
    • All patients must fulfill the criteria for SSc by American College of Rheumatology (ACR) criteria (Subcommittee for Scleroderma Criteria 1980).
    • FVC < 85% of predicted.
    • SSc for no more than 7 years with onset defined as the date of the first non-Raynaud manifestation.
    • Patients may have limited (cutaneous thickening distal but not proximal to elbows and knees, with or without facial involvement) or diffuse (cutaneous thickening proximal to elbows and knees, often involving the chest or abdomen) cutaneous SSc (Medsger 1995).
    • Abnormal DLCO and abnormalities on the plain chest radiograph are not required, although a normal DLCO would be unusual in the face of significant ventilatory restriction due to SSc lung disease.
  • To be eligible to take study medication, the patient must meet not only the criteria above, but also must have ≥ 3.0% neutrophils or ≥ 2.0% eosinophils in screening BAL fluid and/or ground glass opacification on HRCT.
  • Women of childbearing potential should have a negative serum or urine pregnancy test with a sensitivity of at least 50 mIU/mL within 1 week before beginning therapy. CellCept therapy will not be initiated until a report of a negative pregnancy test has been obtained.
  • Effective contraception must be used before beginning CellCept therapy, during therapy, and for 6 weeks following discontinuation of therapy, even where there has been a history of infertility, unless due to hysterectomy. Two reliable forms of contraception must be used simultaneously unless abstinence is the chosen method. If pregnancy does occur during treatment, the physician and patient should discuss the desirability of continuing the pregnancy.

Exclusion Criteria:

  • FVC < 45% of predicted or DLCO (corrected for hemoglobin [Hgb] but not for alveolar volume) < 35% of predicted (suggestive of severe, probably irreparable, disease).
  • Leukopenia (white blood cell count < 4000) or thrombocytopenia (platelet count < 100,000).
  • Serum creatinine ≥ 2.0 mg/dl.
  • Pregnancy, breast feeding, unreliability, drug abuse, or chronic debilitating disease.
  • Uncontrolled congestive heart failure.
  • Active infection of the lung, or elsewhere, whose management would be compromised by mycophenolate mofetil.
  • Prior treatment for alveolitis with mycophenolate mofetil or prior or current treatment for alveolitis with: D-penicillamine, methotrexate, colchicine, Potaba, or azathioprine.
  • Other serious concomitant medical illness (e.g., cancer).
  • Forced expiratory volume in 1 second (FEV1)/FVC ratio < 65%.
  • If of childbearing potential, failure regularly to be employing two reliable means of contraception (i.e., condom, abstinence, intrauterine device (IUD), tubal ligation, vasectomy)
  • Pulmonary hypertension (defined as an estimated systolic blood pressure (SBP) ≥ 35 mmHg measured by echocardiogram).
  • Smoking of cigars, pipes, or cigarettes during the past 6 months.
  • Clinically significant abnormalities on chest x-ray or HRCT scan other than interstitial lung disease (e.g., lung mass, evidence of active pulmonary infection).
  • Use of prednisone (or equivalent) in doses > 10 mg per day.
  • Does not have ≥ 3.0% neutrophils or ≥ 2.0% eosinophils on screening BAL fluid and does not have ground glass opacification on HRCT.
  • Unable to take oral medication.
  • Not able to comply with study procedures in the opinion of the investigator.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00333437

Layout table for location information
United States, California
UCSF, 400 Parnassus Ave
San Francisco, California, United States, 94143
Sponsors and Collaborators
University of California, San Francisco
Roche Pharma AG
Layout table for investigator information
Principal Investigator: Jeffrey A Golden, MD University of California, San Francisco
Layout table for additonal information
Responsible Party: University of California, San Francisco Identifier: NCT00333437    
Other Study ID Numbers: CEL371
First Posted: June 5, 2006    Key Record Dates
Results First Posted: May 17, 2013
Last Update Posted: November 13, 2013
Last Verified: September 2013
Keywords provided by University of California, San Francisco:
Scleroderma, Systemic
Additional relevant MeSH terms:
Layout table for MeSH terms
Scleroderma, Systemic
Scleroderma, Diffuse
Scleroderma, Localized
Connective Tissue Diseases
Skin Diseases
Mycophenolic Acid
Antibiotics, Antineoplastic
Antineoplastic Agents
Antibiotics, Antitubercular
Antitubercular Agents
Anti-Bacterial Agents
Anti-Infective Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action